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Results of a phase I Study of Bendamustine in Combination with Ofatumumab, Carboplatin and 
Etoposide (BOCE) for Refractory or Relapsed Aggressive B-cell Non Hodgkin’s Lymphomas (NHL) 
 
Sameh Gaballa, MD, Neil Palmisiano, MD, Aakanksha Asija, MD, Andrew Chapman, DO, Jennifer K. Cloud, BS, Joanne Filicko-O’Hara, MD, Lewis 
Rose, MD, Michael Ramirez, MD, Onder Alpdogan, MD, Neal Flomenberg, MD, Barbara Pro, MD, Elena Gitelson, MD, PhD, Mark Weiss, MD 
Department of  Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 
•  There are a number of  regimens used to treat relapsed/
refractory aggressive lymphomas and little consensus exists 
on the best salvage treatment. 
•  No regimen has shown clear superiority but uniformly there 
was an inferior outcome among patients who had relapsed 
after a prior rituximab containing regimen.  
•  Ofatumumab is a fully human IgG1 monoclonal anti-
CD20 antibody. It recognizes a distinct epitope on the 
human CD20 molecule. In vitro studies with ofatumumab 
have shown more complement dependent cytotoxicity than 
rituximab.  
•  Bendamustine has single agent activity in relapsed 
aggressive lymphomas and has a favorable safety profile.  
 
•  We conducted a phase I trial using a novel RICE-like 
salvage combination regimen in which ofatumumab is 
substituted for rituximab and bendamustine replaces 
ifosfamide in combination with carboplatin and etoposide 
(BOCE) to assess the safety and toxicity profile of  this 
combination.  
•  The objective from the phase I part of  this trial was to assess 
safety and tolerability of  this combination.  
•  Eligibility: 
–  Relapsed or refractory aggressive B cell lymphoid 
malignancies after at least one prior chemotherapy regimen  
–  Measurable disease and adequate organ function.  
•  Design:  
–  Standard 3+3 design using escalated doses of  
bendamustine  [70, 90, and 120 mg/m2 Day (D) 1-2], fixed 
doses of  ofatumumab (cycle 1: 300 mg D1, 1000mg D3, 
cycle 2 and 3: 1000mg D1), Carboplatin (Carboplatin 
AUC 5 D2) and Etoposide (100mg/m2 D 1-3).   
–  All patients received growth factor support.  
–  Patients were evaluated for response after cycle 2 with a CT 
scan and after cycle 3 with a PET-CT scan.   
–  The first cycle was administered in the inpatient setting, 
while subsequent cycles were administered in the 
outpatient department. 
•  After 3 BOCE cycles, overall response rate was 64% [CR: 5 
patients (46%); PR: 2 patients(18%)].  
•  Two patients (18%) had progressive disease and 1 patient 
(9%) had stable disease. One patient was not evaluable for 
response.  
•  Five patients (46%) subsequently underwent an allogeneic 
transplant. 
•  Five patients (45%) eventually died, all of  progressive 
disease. 
 
•  The BOCE regimen is well tolerated in patients with 
relapsed or refractory aggressive B cell lymphomas  
•  An important benefit of  this regimen compared to most 
salvage therapies is that this regimen can be largely 
administered in the outpatient setting.  
•  Most responses were seen at the 90 mg/m2 and 120 mg/m2 
in this small phase I cohort.  
•  Bendamustine at the dose of  120 mg/m2 is currently being 
utilized in the phase II portion of  the trial which is ongoing 
to assess efficacy.   
 
 
 
 
 
Introduction!
Objectives!
Methods!
Patient Characteristics!
Conclusions!•  Incidence of  non-hematologic toxicity was in line with other 
carboplatin based regimens  
•  Dose limiting toxicity was not reached.  
•  Six serious adverse events (SAEs) were reported in 4 patients and 
included: 
–  Acute kidney injury, urinary tract infection, pleural effusion, 
lower GI bleeding, thromboembolic event and febrile neutropenia 
•  3 patients required hospitalization within 30 days from the 
chemotherapy cycle. 
•  No patient discontinued therapy due to toxicity. 
•  Infusion related reactions occurred in 27% of  patients and were all 
grade I-II. 
Regimen Saftey!
Grade III-IV toxicity!
Neutropenia! n= 9 (82%)!
Thrombocytopenia! n= 7 (64%)!
Anemia! n=7 (64%)!
Lymphopenia! n= 3 (27%)!
Febrile Neutropenia! n= 3 (27%)!
Hyponatremia! n=2 (18%)!
Hypophosphatemia! n=2 (18%)!
Age Sex Diagnosis Disease 
Status 
sAAIPI No. of 
Prior 
Therapies 
Last Therapy 
Received 
No of 
Cycles 
Received 
Bendamustine 
dose (mg/m2) 
Response 
Patient 1 72 Male DLBCL Refractory High-intermediate 2 R-Bendamustine 3 70 PD 
Patient 2 62 Male DLBCL Refractory Low-intermediate 1 R-CHOP 3 70 SD 
Patient 3 63 Male Follicular G3A Relapsed Low-intermediate 2 R-CHOP 3 70 PD 
Patient 4 62 Male Follicular G3B Relapsed High risk 3 R-Bendamustine 1 70 NA 
Patient 5 75 Female Mantle cell lymphoma Relapsed Low-intermediate 1 R-CHOP 3 70 CR 
Patient 6 54 Female DLBCL Relapsed High-intermediate 2 R-CHOP 3 90 PR 
Patient 7 53 Male Follicular G3B Relapsed Low-intermediate 1 R-CHOP 3 90 CR 
Patient 8 56 Male Transformed CLL Refractory Low-intermediate 2 R-CHOP 3 90 CR 
Patient 9 57 Female DLBCL Refractory High-intermediate 1 R-CHOP 2 120 CR 
Patient 10 63 Male DLBCL Refractory High-intermediate 3 R-CHOP 3 120 PR 
Patient 11 65 Female Follicular G3B Relapsed Low-intermediate 1 R-CHOP 3 120 CR 
All patients with refractory disease were refractory to rituximab.  
All patients had stage III or IV disease.  
